Jacob van Naarden, Chief Business Officer at Loxo Oncology, Inc. (LOXO), sold 12,200 shares at $165.13 ($2.0M) on 2018-10-03, disclosed to the SEC on 2018-10-05.
Open-market sale of $2.0M LOXO by Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $165.13 | 2,000 | $330K | 16.4% |
| 2 | $165.88 | 400 | $66K | 3.3% |
| 3 | $167.19 | 500 | $84K | 4.2% |
| 4 | $168.85 | 2,300 | $388K | 19.3% |
| 5 | $169.40 | 300 | $51K | 2.5% |
| 6 | $160.62 | 600 |
| $96K |
| 4.8% |
| 7 | $161.52 | 1,100 | $178K | 8.8% |
| 8 | $162.70 | 1,194 | $194K | 9.7% |
| 9 | $162.70 | 1,194 | $194K | 9.7% |
| 10 | $163.78 | 1,006 | $165K | 8.2% |
| 11 | $163.78 | 1,006 | $165K | 8.2% |
| 12 | $164.68 | 600 | $99K | 4.9% |
| Total | $164.78 avg | 12,200 | $2.0M | 100% |
| Filing → |
| LOXO | SELL | 2018-11-28 | $1.5M | — | Filing → |
| LOXO | SELL | 2018-09-14 | $2.8M | — | Filing → |
| LOXO | SELL | 2018-08-15 | $2.9M | — | Filing → |